STELLA PHARMA CORPORATION Logo

STELLA PHARMA CORPORATION

Develops boron drugs for Boron Neutron Capture Therapy (BNCT), a targeted cancer radiation treatment.

4888 | T

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
Japan
Address:
大阪市中央区高麗橋三丁目2番7号 ORIX高麗橋ビル
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Stella Pharma Corporation is a pharmaceutical company engaged in the research, development, manufacturing, and sales of innovative drugs. The company specializes in Boron Neutron Capture Therapy (BNCT), a targeted radiation treatment for cancer. Its primary focus is on the development of boron compounds, including its approved drug Steboronine®, which is administered to patients prior to neutron irradiation. This therapy is primarily used for treating unresectable, locally advanced, or recurrent head and neck cancer. Stella Pharma aims to contribute to global healthcare by advancing BNCT as a new standard of care for various types of cancer.

This is a Fraction of the Available Data.

You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for STELLA PHARMA CORPORATION and 9,000+ other companies.

Stop analyzing yesterday's news. Start building a real-time advantage.

Request Enterprise API Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-06-26 07:06
Regulatory News Service
確認書
Japanese 8.1 KB
2025-06-26 07:05
Annual Report
有価証券報告書-第18期(2024/04/01-2025/03/31)
Japanese 1.2 MB
2025-06-26 07:05
Regulatory News Service
内部統制報告書-第18期(2024/04/01-2025/03/31)
Japanese 21.7 KB
2025-06-25 06:52
Post-Annual General Meeting Information
臨時報告書
Japanese 21.4 KB
2024-11-12 05:07
Report Publication Announcement
確認書
Japanese 8.1 KB
2024-11-12 05:06
Interim Report
半期報告書-第18期(2024/04/01-2025/03/31)
Japanese 192.3 KB
2024-07-01 02:34
Post-Annual General Meeting Information
臨時報告書
Japanese 28.0 KB
2024-06-28 07:05
Governance Information
内部統制報告書-第17期(2023/04/01-2024/03/31)
Japanese 21.3 KB
2024-06-28 07:04
Registration Form
確認書
Japanese 8.1 KB
2024-06-28 07:04
Annual Report
有価証券報告書-第17期(2023/04/01-2024/03/31)
Japanese 1.1 MB
2024-02-14 05:13
Quarterly Report
四半期報告書-第17期第3四半期(2023/10/01-2023/12/31)
Japanese 145.0 KB
2024-02-14 05:13
Regulatory News Service
確認書
Japanese 8.1 KB
2023-11-14 06:08
Report Publication Announcement
確認書
Japanese 8.1 KB
2023-11-14 06:07
Quarterly Report
四半期報告書-第17期第2四半期(2023/07/01-2023/09/30)
Japanese 172.5 KB
2023-08-10 06:38
Report Publication Announcement
確認書
Japanese 8.1 KB

Automate Your Workflow. Get a real-time feed of all STELLA PHARMA CORPORATION filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for STELLA PHARMA CORPORATION via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
AnGes, Inc. Logo
Develops gene-based medicines like HGF gene therapy, DNA vaccines, and NF-kB decoys.
Japan 4563
ANIMALCARE GROUP PLC Logo
Develops & sells veterinary prescription & OTC medicines for professionals worldwide.
United Kingdom ANCR
Annexin Pharmaceuticals AB Logo
Developing Annexin A5 protein to treat vascular, inflammatory, and cancerous diseases.
Sweden ANNX
ANTEROGEN CO., LTD. Logo
Develops and commercializes adult stem cell therapies and orphan drugs for medical conditions.
South Korea 065660
Antibiotice S.A. Logo
Develops and manufactures generic medicines and APIs, specializing in anti-infectives.
Romania ATB
Apontis Pharma AG Logo
German pharma firm specializing in Single Pills for cardiovascular and chronic diseases.
Germany APPH
AprilBio Co.,Ltd. Logo
Develops long-acting biologic drugs for autoimmune diseases and oncology using its SAFA™ platform.
South Korea 397030
Aprogen Biologics Inc. Logo
Develops and manufactures novel biologic drugs and biosimilars for the professional market.
South Korea 003060
Aprogen, Inc Logo
Develops and manufactures novel biologics and biosimilars for cancer and arthritis treatments.
South Korea 007460
Develops drugs for fibrosis, inflammation, and cancer using NOX inhibitor & CAF modulation tech.
South Korea 293780

Talk to a Data Expert

Have a question? We'll get back to you promptly.